This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/pubchem-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/pubchem-substance/
n8http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/national-drug-code-directory/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n23http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00444/identifier/chemspider/
n25http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00444
rdf:type
n3:Drug
n3:description
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. [PubChem]
n3:dosage
n9:271B50C4-363D-11E5-9242-09173F13E4C5 n9:271B50C5-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
5 hours
n3:indication
Teniposide is used for the treatment of refractory acute lymphoblastic leukaemia
n3:manufacturer
n24:271B50C2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00444 n28:DB00444
dcterms:title
Teniposide
adms:identifier
n12:DB00444 n14:31930 n15:0015-3075-19 n16:34698 n19:C11153 n20:D02698 n21:46507536 n27:Teniposide n29:PA451611
n3:mechanismOfAction
The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. Teniposide binds to and inhibits DNA topoisomerase II. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.
n3:packager
n24:271B50C1-363D-11E5-9242-09173F13E4C5 n24:271B50C0-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
From 4% to 12% of a dose is excreted in urine as parent drug. Fecal excretion of radioactivity within 72 hours after dosing accounted for 0% to 10% of the dose.
n3:synonym
VM-26 NSC-122819 Téniposide 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) HSDB 6546 Teniposido 4'-Demethylepipodophyllotoxin-beta-D-thenylidene glucoside Vumon NSC 122819 Teniposid Epidophyllotoxin Teniposidum
n5:hasAHFSCode
n6:10-00-00
n17:hasConcept
n18:M0021161
foaf:page
n23:teniposide.html n25:teniposide.htm
n3:IUPAC-Name
n4:271B50CA-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B50D0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B50CF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B50CC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B50CD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B50CE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B50C8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B50C6-363D-11E5-9242-09173F13E4C5 n4:271B50C9-363D-11E5-9242-09173F13E4C5 n4:271B50E1-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B50C7-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n26:L01CB02
n3:H-Bond-Acceptor-Count
n4:271B50D6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B50D7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B50D1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B50D2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B50D4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B50D3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B50D5-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
29767-20-2
n3:category
n3:clearance
* 10.3 mL/min/m2
n3:containedIn
n10:271B50C3-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B50DC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B50DE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B50DF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B50E0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B50DB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B50DA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B50DD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B50CB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B50D8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B50D9-363D-11E5-9242-09173F13E4C5